eczema

IPO initial public offering
Biotech

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Attovia has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
Nick Paul Taylor Jul 15, 2026 4:09am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

Jun 22, 2026 7:59am
Money present

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

May 27, 2026 8:57am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am
target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am